Greenwich LifeSciences, Inc. (GLSI) Research

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Market snapshot

Symbol
GLSI
Price
$23.38
Day change
-2.54%
Market cap
$343.2M
P/E ratio
-15.65x
52-week range
7.78-34.1
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$50.00

Peer companies

  • Agenus Inc. (AGEN)
  • Atossa Therapeutics, Inc. (ATOS)
  • Cognition Therapeutics, Inc. (CGTX)
  • TuHURA Biosciences, Inc. (HURA)
  • Immix Biopharma, Inc. (IMMX)
  • Opus Genetics, Inc. (IRD)
  • Oncolytics Biotech Inc. (ONCY)
  • Seer, Inc. (SEER)

Recent insider activity

  • Patel Snehal — P-Purchase (1800 shares) on 2026-01-13
  • Patel Snehal — P-Purchase (2900 shares) on 2026-01-12
  • Patel Snehal — P-Purchase (4300 shares) on 2025-12-31
  • Patel Snehal — P-Purchase (2900 shares) on 2025-12-30
  • Patel Snehal — P-Purchase (4100 shares) on 2025-12-18

Open Greenwich LifeSciences, Inc. (GLSI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.